| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:19566492 | IVTH | 0.0003 - 0.0015 M | 0.0003 - 0.0015 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0003 - 0.0015 M | 0.0003 - 0.0015 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:20726872 | IVTH | 0.0003 - 0.0015 M | 0.0003 - 0.0015 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0003 - 0.0015 M | 0.0003 - 0.0015 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:35254616 | IVR | 6 mg/kg | 6 mg/kg | Changes in neuronal morphology | Neurological endocrine-mediated perturbations |
| IVR | 6 mg/kg | 6 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:35560535 | IVR | 2 - 5 mg/kg | 2 - 5 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased brain weights | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Cognitive impairment | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Neuronal degeneration | Neurological endocrine-mediated perturbations | |
| PMID:37505509 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.